220 related articles for article (PubMed ID: 18483287)
21. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
[TBL] [Abstract][Full Text] [Related]
22. Chinese medicinal herb Scutellaria barbata modulates apoptosis and cell survival in murine and human prostate cancer cells and tumor development in TRAMP mice.
Wong BY; Nguyen DL; Lin T; Wong HH; Cavalcante A; Greenberg NM; Hausted RP; Zheng J
Eur J Cancer Prev; 2009 Aug; 18(4):331-41. PubMed ID: 19444125
[TBL] [Abstract][Full Text] [Related]
23. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
Ghosh R; Graham H; Rivas P; Tan XJ; Crosby K; Bhaskaran S; Schoolfield J; Banu J; Fernandes G; Yeh IT; Kumar AP
Anticancer Res; 2010 Mar; 30(3):857-65. PubMed ID: 20393007
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Bai LY; Chiu CF; Pan SL; Sargeant AM; Shieh TM; Wang YC; Weng JR
Oral Oncol; 2011 Dec; 47(12):1127-33. PubMed ID: 21865079
[TBL] [Abstract][Full Text] [Related]
26. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
29. Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer.
Huss WJ; Lai L; Barrios RJ; Hirschi KK; Greenberg NM
Prostate; 2004 Oct; 61(2):142-52. PubMed ID: 15305337
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Camphausen K; Scott T; Sproull M; Tofilon PJ
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
[TBL] [Abstract][Full Text] [Related]
32. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
33. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Yang YT; Balch C; Kulp SK; Mand MR; Nephew KP; Chen CS
Neoplasia; 2009 Jun; 11(6):552-63, 3 p following 563. PubMed ID: 19484144
[TBL] [Abstract][Full Text] [Related]
34. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
35. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
36. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
37. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake.
Huffman DM; Johnson MS; Watts A; Elgavish A; Eltoum IA; Nagy TR
Cancer Res; 2007 Jan; 67(1):417-24. PubMed ID: 17185379
[TBL] [Abstract][Full Text] [Related]
38. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
39. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
40. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]